CASE REPORT: REASONS FOR NON-ADHERENCE TO ANTIRETROVIRAL THERAPY (ART)IN A RETROVIRAL DISEASE (RVD) PATIENT
Copyright (c) 2019 Ali Shanshool
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Objective: To report a case of an HIV patient who was not compliant to ART medications, and explain the reasons behind that.
Case Summary: This 36 years old Malay female with 49kg was attended toretroviral disease (RVD) Medication Therapy Adherence Clinic (MTAC) at Hospital Sungai Buloh (HSB) to follow up and refill her antiretroviral therapy (ART) regimen on 20th August 2018. She has been diagnosed with RVD since 2004, but started her highly active antiretroviral therapy (HAART) since 2008 when she visited HSB for the first time. She was given a variety combination of HAART regimens from 2008 until 2018, and developed resistance to some of them due to her poor compliance. ART medications’ side effects and number of pills are the main reason to default the medications. Consequently, she has failed the first line regimen, and currently has not had any good treatment regimen with virological suppressions.
Discussion:Treatment adherence is generally regarded as an important factor in achieving optimal outcomes across many disease states; in the treatment of human immunodeficiency virus (HIV), poor adherence to treatment has the potential to impact outcomes on multiple levels. The causes of poor adherence to ART are extremely diverse, and include complexity of therapeutic regimens (eg, pill burden and dosing frequency), and treatment side effects. Treatment approaches, such as the use of fixed-dose combinations of ART agents to reduce dosing complexity, giving symptomatic treatments to treat the side effects, as well as educational interventions, such as medication therapy management initiatives, have been shown to improve adherence to therapy in HIV.
Conclusion:A case of patient, who has failed multiple HAART regimens, was presented and reasons that lead the patient to have poor compliance and developed resistance to certain ART drugs were discussed.
2. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939-941.
3. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146(8):564-573.
4. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006; 20(2):223-231.
5. Maggiolo F, Airoldi M, Kleinloog HD, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials. 2007;8(5):282-292.
6. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; Panel on Antiretroviral Guidelines for Adults and Adolescents. http://aidsinfo.nih.gov/ContentFiles/Adultand AdolescentGL.pdf. Accessed July 17, 2013.
7. Schaecher KL. The importance of treatment adherence in HIV.The American journal of managed care. 2013 Sep;19(12 Suppl):s231-7.
8. Chandwani A, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Therapeutics and clinical risk management. 2008 Oct;4(5):1023.
9. Hill A, Balkin A. Risk factors for gastrointestinal adverse events in HIV treated and untreated patients. AIDS Rev. 2009;11(1):30-38.
10. Wilcox CM, Saag MS. Gastrointestinal complications of HIV infection: changing priorities in the HAART era. Gut. 2008;57(6):861-870.
11. Wegzyn CM, Fredrick LM, Stubbs RO, Woodward WC, Norton M. Diarrhea associated with lopinavir/ritonavir-based therapy: results of a meta-analysis of 1469 HIV-1-infected participants. Journal of the International Association of Physicians in AIDS Care. 2012 Aug;11(4):252-9.
12. O’Connor JL, Gardner EM, Mannheimer SB, et al. Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial. J Infect Dis. 2013;208(1):40-49.
13. Cooper V, Horne R, Gellaitry G, et al. The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study. J Acquir Immune DeficSyndr. 2010;53(3):369-377.